1. Home
  2. TGLS vs HROW Comparison

TGLS vs HROW Comparison

Compare TGLS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$37.67

Market Cap

1.6B

ML Signal

HOLD

HROW

Harrow Inc.

SELL

Current Price

$28.84

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TGLS
HROW
Founded
1984
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2011
2008

Fundamental Metrics

Financial Performance
Metric
TGLS
HROW
Price
$37.67
$28.84
Analyst Decision
Buy
Strong Buy
Analyst Count
4
9
Target Price
$55.75
★ $65.00
AVG Volume (30 Days)
333.1K
★ 615.6K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 1.63%
N/A
EPS Growth
N/A
★ 71.43
EPS
★ 1.27
N/A
Revenue
★ $370,984,000.00
N/A
Revenue This Year
$12.44
$28.59
Revenue Next Year
$11.39
$53.17
P/E Ratio
$28.95
★ N/A
Revenue Growth
★ 17.98
N/A
52 Week Low
$34.05
$26.96
52 Week High
$63.46
$54.98

Technical Indicators

Market Signals
Indicator
TGLS
HROW
Relative Strength Index (RSI) 51.76 32.18
Support Level $37.43 $28.54
Resistance Level $46.99 $35.87
Average True Range (ATR) 1.34 1.40
MACD 0.43 -0.08
Stochastic Oscillator 78.08 30.74

Price Performance

Historical Comparison
TGLS
HROW

About TGLS Tecnoglass Inc.

Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: